Second relma-cel infusion for returning B-cell lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial looks at giving a second dose of relma-cel (a type of CAR-T therapy) for B-cell lymphoma that came back or did not fully respond after the first treatment. It may help shrink tumors again, but it requires that side effects from the first treatment and pre-chemo are mostly gone and that you meet infection and blood-test safety checks.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are an adult (18+) with relapsed or refractory B-cell lymphoma and you already finished your first relma-cel treatment
- Your care team has checked your disease after the first relma-cel dose, and they are recommending a second infusion based on your current condition
- Before the second infusion, you can confirm you had enough relma-cel available and the dose plan is acceptable for you
- Your tests show CD19-positive tumor cells are still present (CD19 is a marker on certain lymphoma cells) if your team can safely check
- Your pre-infusion blood tests show no harmful anti-drug antibodies, and side effects from the pre-chemo are back to mild levels (or your normal baseline)
- You must not have serious allergy to the treatment ingredients, and you cannot have uncontrolled infections (fungal, bacterial, viral, or other)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a second infusion of Relma-cel, a CAR-T cell therapy that uses your own immune cells to attack lymphoma. It's for patients whose B-cell lymphoma has come back or not responded to treatment, and who have already had one dose of Relma-cel.
This trial tests a new type of CAR-T cell therapy designed to be stronger against B-cell lymphoma that has come back or not responded to previous treatments. The treatment uses your own immune cells, which are modified in a lab to better attack cancer cells.
This trial tests a combination treatment: a stem cell transplant followed by CAR-T cell therapy for people with B-cell lymphoma that has come back or not responded to treatment. It is for those with high-risk features like large tumors or certain genetic changes.
This trial tests an experimental CAR T-cell therapy for people with large B-cell lymphoma that has come back or not responded to at least two prior treatments. The therapy uses a patient's own immune cells, modified to find and attack cancer cells.
This study is for people who have already been treated with Relma-cel, a type of CAR-T cell therapy for blood cancers. It is not a new treatment but a way to collect more information about how Relma-cel works over time.
This Phase 1 study tests whether a second re-infusion of axicabtagene ciloleucel (CAR-T) is safe in people with aggressive B-cell non-Hodgkin lymphoma that came back or did not respond after standard second-line CAR-T. It may help some patients by trying to improve disease control while carefully monitoring side effects.
Hear when a new Relapsed or Refractory B-cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.